Mantle Cell Non-Hodgkin's Lymphoma

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer... Continue Reading

Revlimid®/Rituxin® Highly Active as Initial Therapy for Mantle Cell Lymphoma (December 10, 2015)

The treatment combination consisting of Revlimid® (lenalidomide) plus Rituxan® (rituximab) provides high rates of long-lasting anti-cancer responses when used as initial therapy for mantle cell lymphoma.... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

What’s New in the Management of Lymphoma? (March 2, 2015)

What’s New in the Management of Lymphoma? Cancers that begin in cells of the lymph system are referred to as malignant lymphomas. Lymphomas range from aggressive to slow growing or indolent and can be... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

CancerConnect News: HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

Initial Treatment with VELCADE® Improves Outcomes of Patients with Mantle Cell Lymphoma (July 10, 2014)

The results of a large comparative clinical trial presented at the annual meeting of the American Society of Clinical Oncology demonstrated that VELCADE® (bortezomib)-based combination therapy demonstrated... Continue Reading

Imbruvica Approved for Mantle Cell Lymphoma (January 23, 2014)

The U.S. Food and Drug Administration (FDA) has approved Imbruvica™ (ibrutinib) for the treatment of patients with mantle cell lymphoma, a rare and aggressive type of blood cancer. Non-Hodgkin’s lymphoma... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published... Continue Reading

Revlimid Approved for Mantle Cell Lymphoma (July 12, 2013)

The U.S. Food and Drug Administration (FDA) has approved Revlimid® (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies,... Continue Reading

Epigenetic Therapy Promising in Mantle Cell Lymphoma (July 10, 2013)

An epigenetic/immunotherapy regimen of cladribine, Rituxan® (rituximab), and vorinostat produced a 100 percent response rate and complete remissions in 86 percent of patients with newly diagnosed mantle... Continue Reading

R-CHOP Induction Plus Rituxan Maintenance Improves Remission in Older Patients with Mantle Cell Lymphoma (October 23, 2012)

Induction therapy with R-CHOP followed by maintenance with Rituxan® (rituximab) nearly doubled the remission duration in older patients with mantle cell lymphoma, according to the results of a study published... Continue Reading

Treanda More Effective than Standard R-CHOP for Non-Hodgkin’s Lymphoma (June 12, 2012)

The combination of Treanda® (bendamustine) and Rituxan® (rituximab) more than doubled progression-free survival compared with standard R-CHOP therapy among patients with indolent lymphoma and mantle... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients.... Continue Reading

Survivors of Some Childhood Cancers May Face Cognitive Impairment (May 18, 2010)

Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according... Continue Reading

Children and Teens Have Better NHL Survival than Young Adults (March 15, 2010)

Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in... Continue Reading

Cancer Caregivers Devote Substantial Time and Effort (September 9, 2009)

On average, informal caregivers of cancer patients devote more than eight hours per day to caregiving. These results were published in Cancer. Informal caregiving is an important part of cancer management.... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS